Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

 
• By Sue Sutter

Although Samsung has not provided 180-day advance notice of commercialization for Eticovo, its recently approved biosimilar to Enbrel, Amgen seeks a preliminary injunction because it has reason to believe the company is prepared to launch ‘imminently.’

Feet partners on black background
Samsung Bioepis opted not to do the 'patent dance' with Amgen over its etanercept biosimilar. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics